Understanding the promising role of antibody drug conjugates in breast and ovarian cancer

Ritchu Babbar, Vanya, Aarti Bassi, Rashmi Arora, Ankur Aggarwal, Pranay Wal, Sunil Kumar Dwivedi, Salma Alolayan, Monica Gulati, Celia Vargas-De-La-Cruz, Tapan Behl, Shreesh Ojha

Research output: Contribution to journalArticlepeer-review

Abstract

A nascent category of anticancer therapeutic drugs called antibody-drug conjugates (ADCs) relate selectivity of aimed therapy using chemotherapeutic medicines with high cytotoxic power. Progressive linker technology led to the advancement of more efficacious and safer treatments. It offers neoteric as well as encouraging therapeutic strategies for treating cancer. ADCs selectively administer a medication by targeting antigens which are abundantly articulated on the membrane surface of tumor cells. Tumor-specific antigens are differently expressed in breast and ovarian cancers and can be utilized to direct ADCs. Compared to conventional chemotherapeutic drugs, this approach enables optimal tumor targeting while minimizing systemic damage. A cleavable linker improves the ADCs because it allows the toxic payload to be distributed to nearby cells that do not express the target protein, operating on assorted tumors with dissimilar cell aggregation. Presently fifteen ADCs are being studied in breast and ovarian carcinoma preclinically, and assortment of few have already undergone promising early-phase clinical trial testing. Furthermore, Phase I and II studies are investigating a wide variety of ADCs, and preliminary findings are encouraging. An expanding sum of ADCs will probably become feasible therapeutic choices as solo agents or in conjunction with chemotherapeutic agents. This review accentuates the most recent preclinical findings, pharmacodynamics, and upcoming applications of ADCs in breast and ovarian carcinoma.

Original languageEnglish
Article numbere21425
JournalHeliyon
Volume9
Issue number11
DOIs
Publication statusPublished - Nov 2023

Keywords

  • Antibody-drug conjugate
  • Breast cancer
  • Cleavable linker
  • Ovarian cancer
  • Payload
  • Therapy

ASJC Scopus subject areas

  • General

Fingerprint

Dive into the research topics of 'Understanding the promising role of antibody drug conjugates in breast and ovarian cancer'. Together they form a unique fingerprint.

Cite this